[go: up one dir, main page]

MA43918A - Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 - Google Patents

Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31

Info

Publication number
MA43918A
MA43918A MA043918A MA43918A MA43918A MA 43918 A MA43918 A MA 43918A MA 043918 A MA043918 A MA 043918A MA 43918 A MA43918 A MA 43918A MA 43918 A MA43918 A MA 43918A
Authority
MA
Morocco
Prior art keywords
antagonist
prevention
treatment
pharmaceutical composition
active substance
Prior art date
Application number
MA043918A
Other languages
English (en)
Inventor
Yoshinobu Higuchi
Keiko Hirokawa
Yuki Iwayanagi
Akihisa Kaneko
Hidetomo Kitamura
Hiroaki Matsushita
Ryosuke Mihara
Tomohisa Saito
Yumi Yamamoto
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MA43918A publication Critical patent/MA43918A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA043918A 2015-04-14 2016-04-13 Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 MA43918A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015082699 2015-04-14
JP2016041641 2016-03-04

Publications (1)

Publication Number Publication Date
MA43918A true MA43918A (fr) 2018-12-05

Family

ID=57126544

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043918A MA43918A (fr) 2015-04-14 2016-04-13 Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31

Country Status (14)

Country Link
US (2) US10544227B2 (fr)
EP (1) EP3284480B1 (fr)
JP (6) JP6654967B2 (fr)
KR (1) KR20170134748A (fr)
CN (1) CN107614016B (fr)
BR (1) BR112017022101A2 (fr)
CA (1) CA2980992C (fr)
MA (1) MA43918A (fr)
MX (2) MX390570B (fr)
NO (1) NO2025047I1 (fr)
PT (1) PT3284480T (fr)
RU (1) RU2749512C2 (fr)
TW (4) TW202515609A (fr)
WO (1) WO2016167263A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202515609A (zh) 2015-04-14 2025-04-16 日商中外製藥股份有限公司 含有il-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物
KR102886159B1 (ko) 2015-04-14 2025-11-13 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
WO2017126488A1 (fr) * 2016-01-18 2017-07-27 持田製薬株式会社 Composition de traitement du psoriasis et procédé de traitement
WO2018156180A1 (fr) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anticorps anti-il31 à usage vétérinaire
HRP20251101T1 (hr) * 2018-02-09 2025-11-21 Galderma Holding SA Nemolizumab u liječenju atopijskog dermatitisa s umjerenom do teškom ekskoriacijom
CN112512480B (zh) 2018-05-21 2024-10-01 中外制药株式会社 被封入玻璃容器的冷冻干燥制剂
MA54657A (fr) * 2019-01-03 2021-11-10 Invetx Inc Compositions pour augmenter la demi-vie d'un agent thérapeutique chez les chiens et procédés d'utilisation
BR112022002771A2 (pt) * 2019-08-29 2022-08-09 Kindred Biosciences Inc Anticorpos anti-il31 para uso veterinário
CN110563844A (zh) * 2019-09-04 2019-12-13 华中农业大学 一种抗犬白介素31受体的多克隆抗体及其应用
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.
WO2021151059A1 (fr) * 2020-01-24 2021-07-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Composés et procédés de traitement ou de réduction de prurit
JPWO2022113316A1 (fr) * 2020-11-30 2022-06-02
US20220411518A1 (en) * 2021-04-07 2022-12-29 Galderma Holding S.A. Treatments for prurigo nodularis
CN115181183B (zh) * 2022-06-23 2023-11-03 恺佧生物科技(上海)有限公司 一种il-31ra抗体以及其构建方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH575014A5 (fr) 1973-05-25 1976-04-30 Alusuisse
JPS5328498Y2 (fr) 1973-08-17 1978-07-18
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
BR9204244A (pt) 1992-10-26 1994-05-03 Cofap Ferro fundido cinzento
PL309249A1 (en) 1992-12-01 1995-10-02 Protein Design Labs Humanised antibodies against l-selectin
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
FR2729855A1 (fr) 1995-01-26 1996-08-02 Oreal Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
JP3946256B2 (ja) 1995-09-11 2007-07-18 協和醗酵工業株式会社 ヒトインターロイキン５受容体α鎖に対する抗体
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
CN1241944A (zh) 1996-12-05 2000-01-19 乔治敦大学 具有抗病毒活性的鼠尾草种类的提取物
JPH11101542A (ja) 1997-09-29 1999-04-13 Sanyo Electric Co Ltd 冷蔵庫
JP3979008B2 (ja) 1998-04-30 2007-09-19 タノックス インコーポレイテッド Ｇ−ｃｓｆレセプターアゴニスト抗体及びそのスクリーニング方法
FR2780062B1 (fr) 1998-06-17 2000-07-28 Rhone Poulenc Rorer Sa Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
CA2330547A1 (fr) 1998-06-24 1999-12-29 Chugai Research Institute For Molecular Medicine, Inc. Nouvelles proteines receptrices d'hemopo?etine
DE69934967T2 (de) 1998-12-08 2007-12-06 Biovation Ltd. Verfahren zur verminderung der immunogenität von proteinen
EP2325316B8 (fr) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Protéine réceptrice d'hémopoïétine, NR10
AU7445900A (en) 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
CN1326880A (zh) 2000-06-06 2001-12-19 周伟中 双层站台火车站
US20030096339A1 (en) 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
ES2593002T3 (es) 2000-06-26 2016-12-05 Zymogenetics, Inc. Receptor ZCYTOR17 de citocina
WO2002077230A1 (fr) 2001-03-26 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Variants d'epissage nr10
CN100469793C (zh) 2001-04-05 2009-03-18 株式会社免疫生物研究所 抗骨桥蛋白抗体及其用途
PT1576112E (pt) 2002-01-18 2012-05-25 Zymogenetics Inc Multímeros de receptor de citocina zcytor17
RU2360923C2 (ru) 2002-01-18 2009-07-10 Займоджинетикс, Инк. Новый лиганд рецептора цитокина zcytor17
ATE431406T1 (de) 2002-02-25 2009-05-15 Genentech Inc Neuer typ-1-cytokinrezeptor glm-r
RU2320366C2 (ru) 2002-05-01 2008-03-27 Шеринг Акциенгезельшафт Новые слитые белки тромбомодулина, обеспечивающие направленный перенос к тканевому фактору, в качестве антикоагулянтов
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
TW200407335A (en) 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
KR100499989B1 (ko) 2002-12-27 2005-07-07 네오바이오다임 주식회사 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 면역크로마토그래피 스트립 및 이 스트립를 이용한 아사이알로 α1-산 당단백질 측정방법
US20040223970A1 (en) 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
AU2004229311B2 (en) 2003-03-04 2009-07-09 Alexion Pharmaceuticals, Inc. Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
AU2004223836A1 (en) 2003-03-24 2004-10-07 Zymogenetics, Inc. Anti-IL-20 antibodies and binding partners and methods of using in inflammation
WO2005079566A2 (fr) 2004-02-12 2005-09-01 Lexicon Genetics Incorporated Nouvelles disruptions geniques, compositions et procedes associes
US20060019342A1 (en) 2004-06-25 2006-01-26 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
KR100624013B1 (ko) 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
EP1671642A1 (fr) 2004-12-15 2006-06-21 Universite D'angers Composés contenant des (ant)agonistes de l'oncostatin M (OSM), IL-31 et IFN-gamma pour moduler la migration et fonction de keratinocytes au moyen d'un recepteur comprenant l'OSMRbeta comme sousunité, et applications correspondantes
MX2007007935A (es) 2004-12-28 2007-12-06 Innate Pharma Sa Anticuerpos monoclonales contra nkg2a.
ES2579758T3 (es) 2005-01-28 2016-08-16 Zymogenetics, Inc. Preparaciones homogéneas de IL-31
AU2006214404B2 (en) 2005-02-14 2012-03-08 Bristol-Myers Squibb Company Methods of treating skin disorders using an IL-31RA antagonist
JP2008530137A (ja) 2005-02-14 2008-08-07 ザイモジェネティクス，インコーポレイティド 皮膚リンパ球抗原陽性細胞により仲介される疾患を治療するための方法
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7531637B2 (en) * 2005-05-06 2009-05-12 Zymogenetics, Inc. IL-31 monoclonal antibodies
JP2009526756A (ja) 2006-01-10 2009-07-23 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１ｒａアンタゴニストおよびｏｓｍｒｂアンタゴニストを用いて神経組織における疼痛および炎症を治療する方法
AU2007207764B2 (en) 2006-01-12 2012-06-07 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
RS51723B2 (sr) 2006-03-23 2018-03-30 Bioarctic Neuroscience Ab Poboljšana antitela selektivna za protofibrile i njihova primena
PT2047863E (pt) 2006-06-08 2013-10-21 Chugai Pharmaceutical Co Ltd Prevenção ou tratamento para doença inflamatória
WO2007147122A2 (fr) 2006-06-15 2007-12-21 The Board Of Trustees Of The University Of Arkansas Anticorps monoclonaux qui reconnaissent sélectivement des composés de méthamphétamine et de type méthamphétamine
SI2594586T1 (sl) 2006-09-01 2014-11-28 Zymogenetics, Inc. IL-31 monoklonska protitelesa in metode uporabe
JP2010512402A (ja) 2006-12-11 2010-04-22 ワイス エルエルシー Ｉｌ−１３関連障害を治療するための方法および組成物ならびにその治療をモニター観察するための方法
CN101600456A (zh) * 2006-12-11 2009-12-09 惠氏公司 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物
DE602008004296D1 (de) 2007-02-14 2011-02-17 Vaccinex Inc Humanisierte anti-cd100-antikörper
SI2426144T1 (sl) 2007-02-23 2019-02-28 Merck Sharp & Dohme Corp. Umetno proizvedena anti-IL23P19 antitelesa
EP2138576A4 (fr) 2007-03-16 2011-02-23 Kyowa Hakko Kirin Co Ltd Anticorps anti-claudine-4
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
WO2009007272A1 (fr) 2007-07-10 2009-01-15 F. Hoffmann-La Roche Ag Nouvelle formulation
RU2526512C2 (ru) 2007-09-26 2014-08-20 Чугаи Сейяку Кабусики Кайся Модифицированная константная область антитела
AU2008304756B8 (en) 2007-09-26 2015-02-12 Chugai Seiyaku Kabushiki Kaisha Anti-IL-6 receptor antibody
CN101874042B9 (zh) * 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
BRPI0821145B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo anti-nr10 como agente preventivo ou terapêutico para prurido
WO2009072604A1 (fr) 2007-12-05 2009-06-11 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-nr10 et son utilisation
WO2009071696A2 (fr) 2007-12-07 2009-06-11 Zymogenetics, Inc. Molécules d'anticorps humanisés spécifiques pour il-31
KR20160062207A (ko) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
EP2475376B1 (fr) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations pour enzymes lysosomales
EP2735315B1 (fr) 2011-07-19 2019-10-02 Chugai Seiyaku Kabushiki Kaisha Préparation à teneur en protéines stable renfermant de l'argininamide ou de la valinamide
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
ES2981062T3 (es) 2012-09-07 2024-10-07 Regeneron Pharma Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R
US9198898B2 (en) * 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
WO2014208645A1 (fr) * 2013-06-28 2014-12-31 中外製薬株式会社 Méthode de prédiction de la réponse d'un patient atteint d'une maladie prurigineuse à une thérapie avec antagoniste de l'il-31
TW202515609A (zh) 2015-04-14 2025-04-16 日商中外製藥股份有限公司 含有il-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物
WO2018156367A1 (fr) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anticorps anti-il31 à usage vétérinaire
GB201703063D0 (en) 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
EP3609916A1 (fr) 2017-04-11 2020-02-19 Kiniksa Pharmaceuticals, Ltd. Formulation stable d'anticorps anti-osmr
CN112512480B (zh) 2018-05-21 2024-10-01 中外制药株式会社 被封入玻璃容器的冷冻干燥制剂
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.
IL300694A (en) 2020-09-01 2023-04-01 Chugai Pharmaceutical Co Ltd A pharmaceutical preparation for the prevention and/or treatment of dialysis pruritus that includes an IL-31 antagonist as an active ingredient

Also Published As

Publication number Publication date
US20180079817A1 (en) 2018-03-22
EP3284480B1 (fr) 2025-07-02
NO2025047I1 (no) 2025-10-23
US11773173B2 (en) 2023-10-03
CA2980992A1 (fr) 2016-10-20
JP2021193124A (ja) 2021-12-23
MX390570B (es) 2025-03-20
JP2023134842A (ja) 2023-09-27
WO2016167263A1 (fr) 2016-10-20
PT3284480T (pt) 2025-07-29
JP6654967B2 (ja) 2020-02-26
EP3284480A4 (fr) 2018-12-05
BR112017022101A2 (pt) 2018-07-31
TWI826814B (zh) 2023-12-21
TW202515609A (zh) 2025-04-16
TW202327654A (zh) 2023-07-16
US20200102396A1 (en) 2020-04-02
US10544227B2 (en) 2020-01-28
TWI738648B (zh) 2021-09-11
CA2980992C (fr) 2024-01-23
JP2017160178A (ja) 2017-09-14
CN107614016A (zh) 2018-01-19
JP2020075937A (ja) 2020-05-21
RU2749512C2 (ru) 2021-06-11
EP3284480A1 (fr) 2018-02-21
MX2021013139A (es) 2021-11-25
KR20170134748A (ko) 2017-12-06
RU2017138551A (ru) 2019-05-14
JP6887212B2 (ja) 2021-06-16
MX2017013141A (es) 2018-02-21
JP2025122131A (ja) 2025-08-20
CN107614016B (zh) 2022-06-17
TW202146048A (zh) 2021-12-16
JP2021105051A (ja) 2021-07-26
RU2017138551A3 (fr) 2019-09-30
TW201642905A (zh) 2016-12-16

Similar Documents

Publication Publication Date Title
MA43918A (fr) Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
EP2818482A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
EP2824114A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
MA43709A (fr) Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations
EP2832366A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer de la vésicule biliaire
EP2532364A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
BR112015026307A2 (pt) heterociclo bicíclicos como inibidores de fgfr
EP3375448A4 (fr) Souche ayant la capacité d'inhiber l'obésité et composition pharmaceutique la contenant
FR3032353B1 (fr) Composition pharmaceutique et dispositif pour le traitement de la douleur
EP2825049A4 (fr) Formulation contenant un silicate de calcium particulaire et clonostachys rosea pour le traitement de plantes
EP3539951A4 (fr) Nouveau composé de pyrimidine, son procédé de préparation et composition pharmaceutique le contenant en tant que principe actif pour la prévention ou le traitement du cancer et des maladies inflammatoires
EA201692008A1 (ru) Замещенные сконденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений
EP3403658C0 (fr) Composition pour le traitement des maladies neuro-inflammatoires contenant des cellules souches neurales ou leur sécrétome comme ingrédient actif
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EP3489252A4 (fr) Peptide ayant une activité anticancéreuse, composition pharmaceutique pour le traitement et la prévention du cancer, composition alimentaire de santé fonctionnelle et composition cosmétique fonctionnelle le contenant en tant que principe actif
EP3417853A4 (fr) Composition pharmaceutique pour le traitement d'un cancer, contenant un composé polyphénol utilisé comme principe actif
BR112015026685A2 (pt) agente de diminuição de ácido úrico
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
EP2572721A4 (fr) Composition pharmaceutique comprenant un inhibiteur de hif-2 comme ingrédient actif pour la prévention ou le traitement de l'arthrite
EP3391904A4 (fr) Composition pharmaceutique contenant un anticorps anti-récepteur de la tslp humaine
EP3517133A4 (fr) Composition pharmaceutique contenant un inhibiteur de mtor pour le traitement de la dégénérescence maculaire
EP2962693A4 (fr) Composition pharmaceutique pour la prévention et/ou le traitement d'un cancer
EP3336100A4 (fr) Peptide ayant pour effet de prévenir ou traiter des maladies du système nerveux central et composition pharmaceutique pour la prévention et le traitement de maladies du système nerveux central, contenant ce dernier en tant que principe actif
EP3329929A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de la sécheresse oculaire
EP2857037A4 (fr) Agent de prévention et/ou de traitement d'une douleur neuropathique périphérique causée par un médicament anticancéreux